Advance in the research on P2X7 and inflammatory respiratory diseases.
- Author:
Shu-Hua CAO
1
;
Shao-Peng YUAN
;
Qi HOU
Author Information
1. Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing 100050, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Asthma;
drug therapy;
metabolism;
Humans;
Inflammation;
drug therapy;
metabolism;
Interleukin-18;
metabolism;
Interleukin-1beta;
metabolism;
Lung Neoplasms;
drug therapy;
metabolism;
Mice;
Polymorphism, Single Nucleotide;
Pulmonary Disease, Chronic Obstructive;
drug therapy;
metabolism;
Purinergic P2X Receptor Antagonists;
therapeutic use;
Receptors, Purinergic P2X7;
chemistry;
genetics;
metabolism;
Respiratory Tract Diseases;
drug therapy;
metabolism
- From:
Acta Pharmaceutica Sinica
2013;48(8):1183-1188
- CountryChina
- Language:Chinese
-
Abstract:
P2X7 is the most important subtype of the ATP receptors known so far. Recent investigations showed that the downstream signaling pathway of P2X7 is coupled with several key inflammatory molecules including IL-1beta and IL-18, this suggests P2X7 might have roles in the inflammatory diseases. Moreover, attenuation of P2X7 by selective antagonists in vitro and knockout mice in vivo reducing the inflammatory response indicated that P2X7 is a potential therapeutic target for inflammatory diseases. However, most previous studies on P2X7 were focused on nerve system diseases most, while its effects in inflammatory respiratory diseases, especially in asthma, chronic obstructive pulmonary disease (COPD) and lung cancer have been poorly investigated. In this paper, we reviewed the research progress on the structure, distribution, biological activities of P2X7 and its relationship with inflammatory respiratory diseases including asthma, COPD and lung cancer, along with the development of P2X7 antagonist as therapeutics.
